




International Association of Therapeutic Drug Monitoring  
Annual General Meeting | Tuesday, September 18, 2018

# AGENDA

# Agenda

---

- President
- President Elect
- Past-President
- Secretary
- Treasurer
- Director of Education
- Communications Committee
- TDM Journal





International Association of Therapeutic Drug Monitoring  
Annual General Meeting | Tuesday, September 18, 2018


## President

### Topics to be discussed:


- Michael Oellerich
- Affiliate membership
- Developing countries fund
- Final report Kyoto meeting
- Standard of Practice committee

# Michael Oellerich

---




# Thank you Michael



# Affiliate membership

---


- German Society of Clinical Laboratory (DGKL)
- Japanese Society for TDM
- The International Transplantation Society
- American College of Clinical Pharmacology



# Developing countries fund

---


■ Iguazu: USD \$16,917



# Kyoto 2017

---


- Final report
- Scientific success
- Positive financial balance





# Standard of Practice Committee


- Standards of laboratory practice committee (1997)
- Later Standards of Practice Committee (2012)
- Phillip E. Morgan
- Simon Handley



# Membership Overview

---

Type	Current
Full Member	292
Young Scientist	225
Junior Member	77
Resigned	0
Retired	12
Honorary	6
<b>Total</b>	<b>612</b>



# Membership Overview

Country	Amount	Country	Amount	Country	Amount
Japan	74	South Korea	7	Bulgaria	1
India	68	Taiwan	6	Cameroon	1
USA	68	Thailand	6	Estonia	1
Netherlands	42	Mexico	5	Ethiopia	1
China	33	South Africa	5	Former Yugoslav Republic o	1
Australia	31	Spain	5	Ghana	1
Germany	27	New Zealand	4	Iran	1
Brazil	22	Poland	4	Israel	1
Canada	20	Uzbekistan	4	Jamaica	1
United Kingdom	19	Algeria	3	Kuwait	1
Belgium	18	Nepal	3	Liechtenstein	1
France	17	Tunisia	3	Mali	1
Sweden	12	Turkey	3	Mongolia	1
Norway	11	Czech Republic	2	Nambia	1
Switzerland	10	Denmark	2	Nigeria	1
Argentina	8	Hong Kong	2	Romania	1
Chile	8	Jordan	2	Sri lanka	1
Colombia	8	Rwanda	2	Uruguay	1
Italy	8	Singapore	2	Vietnam	1
Egypt	7	Sudan	2	West Bank and Gaza Strip	1
Malaysia	7	Austria	1	Zimbabwe	1





International Association of Therapeutic Drug Monitoring  
Annual General Meeting | Tuesday, September 18, 2018

## **President-Elect Report**

**Yusuke Tanigawara**

# 15th IATDMCT Congress (2017, Kyoto)

- Congress archives on the web
- <http://www.iatdmct2017.jp/>
- All programs and speakers
- All abstracts
- Pictures
- Final report
- All related information



15th International Congress of  
**Therapeutic Drug Monitoring  
& Clinical Toxicology**  
~Expansion and Evolution of TDM and CT~  
Main Congress: September 24-27, 2017  
Post Congress: September 28, 2017

Kyoto, Japan

IATDMCT 2017  
Mobile App  
Click here!

Home	Welcome Message	Abstracts	Accommodation	Business Meetings	Contact/LOC	Educational Lecture
Registration	Scientific Program	Social Program	Sponsors/Exhibitors	Useful Information	Young Scientists	Venue/Access
Information for Participants	Post-Congress Meeting	Authors Instruction	Japanese Cultural Program	Roundtable Discussion	Daily COMPASS	History


Dear All,  
The 15th Congress of IATDMCT has been a great success, and it has come to an end. On behalf of the Local Organizing Committee, I would like to extend my heartfelt gratitude to all of you for your contributions to this congress. Your participation and support made this congress so fruitful and impressive. Also I believe that you experienced exciting international and interdisciplinary exchanges of knowledge and research findings under the congress theme of "Expansion and Evolution of TDM and CT".  
I thank you again and I look forward to seeing you again in Brisbane in 2018.

Yusuke Tanigawara  
Chair of the 15th Congress of IATDMCT  
Professor, Keio University School of Medicine

Final Report  
IATDMCT Congress 2017

Photos  
Click here!

The Congress surplus USD 70,000 is transferred and saved on 'Developing country fund' for use to support developing countries in future Congresses.




# Upcoming IATDMCT Congresses

---

- 2019 Iguazu, Brazil
- 2020 Banff, Canada
- 2021 Rome, Italy
- 2022 ? / 3 bids



**IATDMCT**  
2019 Congress



# 17th IATDMCT Congress (2019, Iguassu)

- Main Theme "Therapeutic Monitoring of Drugs and Clinical Toxicology for a Globalized World"
- Chair, Dr. Rafael Linden, Universidade Feevale
- Website: [www.iatdmct2019.org](http://www.iatdmct2019.org)




## IATDMCT 2019

17th International Congress of Therapeutic  
Drug Monitoring & Clinical Toxicology

September 22-26, 2019 Foz do Iguassu, Brazil


A screenshot of the IATDMCT 2019 website homepage. The top navigation bar is green and contains the following links: Home, About IATDMCT, Program, Registration, Abstracts, Tourism, General Information, Host City, Sponsors, and Contact. Below the navigation bar is a large banner image of a waterfall. Overlaid on the banner is a dark green box with the text "SAVE THE DATE!" in white, "FOZ DO IGUASSU, BRAZIL" in white, and "RECANTO CATARATAS THERMAS RESORT &amp; CONVENTION" in white. Below this is a green box with the text "September 22-26, 2019" in white. The URL "https://iatdmct2019.org" is visible in the bottom left corner of the banner area.



# 17th IATDMCT Congress (2019, Iguassu)

---

- Important dates
  - 1 October 2018: Registration and abstract submission open
  - 29 March 2019: Abstract submission deadline
  - 31 May 2019: Abstract notification to authors
  - 30 June 2019: Early registration deadline
  - 15 September 2019: Website registration closes
  - 22-26 September 2019: Congress







# 20th Congress in 2022

---

- 3 bids
- Guadalajara, Mexico
- Oslo, Norway
- Prague, Czech Republic

The decided venue will be disclosed at the closing ceremony on Wednesday.





International Association of Therapeutic Drug Monitoring  
Annual General Meeting | Tuesday, September 18, 2018

## Past-President


**Loralie Langman**

# Awards Committee

---

- Because we are moving to annual meetings we are “splitting” the awards we offer each year

Even years - 2018	Odd years - 2019
C.E. Pippenger Award	Irving Sunshine Award
Victor Armstrong Young Investigator Award	Patsalos Prize




# Awards for 2018

---

## ■ C.E. Pippenger Award


- Presented for Outstanding Contributions to Therapeutic Drug Monitoring
- Roger W Jelliffe




# Awards for 2018


---

- Victor Armstrong Young Investigator Award
  - Presented to a Young Investigator for Exceptional Scientific Achievements
  - Laure Elens



- 
- Thank you
  - Merci





International Association of Therapeutic Drug Monitoring  
Annual General Meeting | Tuesday, September 18, 2018

## Secretary Report

**Maria Shipkova**  
Stuttgart, Germany


# Secretary Report

---

## ■ Membership Report

– Updated IATDMCT Membership Summary (as of August 31, 2018)

Type	Total 2017	Total 2018	% Change
Full Member	296 (45%)	292 (48%)	-1.35
Young Scientist	229 (34%)	225 (37%)	-1.75
Junior Member	113 (17%)	77 (13%)	<b>-31.6</b>
Member Award	0	0	0
Resigned	1	0	0
Retired	19	12	<b>-36.8</b>
Honorary	6	6	0
<b>TOTAL</b>	<b>664</b>	<b>612</b>	<b>-7.8</b>





# Secretary Report


---

## ■ Loss Members/Country

- China 28
- Japan 21
- Netherlands 13
- USA 7
- Canada 7

## ■ Gain Members/Country

- India 17
- Australia 10
- Brazil 7
- Columbia 4



# Secretary Report

---




**Member-Get-A-Member Campaign 2018**  
The Campaign started on January 1st and ended on August 31st, 2018.  
The winners get free registration for the Brisbane Congress.

**29 new members in total**

**Congratulations to:**

**Dr. Nicolas Venisse**  
(France)

**Dr. Cindy Lau**  
(Australia)



# Secretary Report

---

## Terms of reference: Affiliate Membership

- The IATDMCT is unique in its goal to promote the interest of Therapeutic Drug Monitoring and Clinical Toxicology internationally. **It collaborates with a selected group of affiliated scientific societies that share its aims particularly on a national level.** This synergistic relationship provides a platform for open collaboration and exchange of knowledge and experiences.
- Members of affiliated societies may join IATDMCT and enjoy the **full function of IATDMCT membership benefits.** Their IATDMCT dues will be reduced by \$ 20 (US) based on the FULL membership or YOUNG SCIENTIST membership fees of IATDMCT. The IATDMCT benefit of a 10% saving on the fee for a two-year membership remains unaffected. The \$ 20 (US)/year discount will apply on top of it.
- Eligible for this membership category are members of scientific societies with which a **respective agreement is in place.** Depending on this agreement additional benefits (e.g. reduction of the dues for the affiliated scientific society) may be available. For further information check with your society.
- The IATDMCT looks forward to expanding the network with other societies with similar visions and interests in Therapeutic Drug Monitoring and Clinical Toxicology to foster personalized medicine worldwide. **Scientific societies interested in this form of collaboration can contact [info@iatdmct.org](mailto:info@iatdmct.org) for more details.**



---

## How to apply for “Affiliate membership” at IATDMCT:

- Login to our website at [www.iatdmct.org](http://www.iatdmct.org)
- Complete the IATDMCT Membership Application Form by selecting “Affiliate membership” as the membership category. To do this you can use either the online- or the PDF application form.
- **Send the form together with a proof of the payment of the membership fee at the partner society to either:**

Email: [info@iatdmct.org](mailto:info@iatdmct.org)


Fax: 1-613-531-0626

Mail to: IATDMCT

4 Cataraqui Street, Suite 310

Kingston ON, K7K 1Z7 Canada

- Pay by Credit Card (we accept Visa and MasterCard) or by Check




# Secretary Report

---

## Affiliate Membership: Potential Partners

- JATDM
- AACP
- TTS
- .....



# Secretary report


---

## ■ Other:

### **Travel grants IATDMCT Congresses:**

- previous rules (5 grants a 2000 \$ US)
- the competition in the past was very strong, numerous applicants with equal quality
- usual practice: only once and preferably citizens of developing countries
- applications from IATDMCT members who are very active for IATDMCT (CC members)

**for 2018: 15 grants a 1000 \$ US**





International Association of Therapeutic Drug Monitoring  
Annual General Meeting | Tuesday, September 18, 2018

## Treasurer Report


**Denise A McKeown**

Forensic Medicine and Science, University of Glasgow  
Glasgow, UK

# 2017 Financials: Overview

---

- 2017 Revenue: **\$304,860** (**\$XXX,XXX**)
  - TDM Journal Royalties: \$260,224
  - Membership Fees: \$41,302
  - Awards Revenue: \$3,334
  - 2017 Congress Surplus: **\$XX,XXX**
- Expenses: **\$182,889**
  - TDM Journal Related: \$113,141
  - Administrative Fees: \$28,291
  - Membership Services: \$41,458
- Surplus: **\$121,971** (**\$XXX,XXX**)






# 2017 Financials: Administration Expenses

---


- Administration Expenses: **\$28,291**
  - Management Fee: \$15,000.00
  - Telecommunications: \$669.69
  - Administration Expenses: \$9,326.71
  - Professional Fees: \$3,294.50



# 2017 Financials: Membership Services Expenses

---


- Membership Services Expenses: **\$41,458**
  - Website: \$4,975.71
  - IATDMCT Compass: \$9037.03
  - Award Winners: \$6,217.71
  - International Travel Grants: \$10,037.00
  - Meetings: \$11,040.07
  - Sundry Expenses: \$150



# 2017 Financials: Summary

---


- IATDMCT Assets
  - Remain strong
- Annual Treasurer Report
  - As a result of 2017 AGM member feedback a detailed Annual Treasurer Report will be produced
  - To be circulated via email to members and posted on the Members Only Area of the IATDMCT website
  - 2017 Report - to be circulated following the finalisation of the 2017 financials
  - 2018 Report - will be circulated once 2018 financials finalised



# Queries or Questions?

---

- Contact
  - [denise.mckeown@glasgow.ac.uk](mailto:denise.mckeown@glasgow.ac.uk)





International Association of Therapeutic Drug Monitoring  
Annual General Meeting | Tuesday, September 18, 2018

## Communications Committee

**Kamisha Johnson-Davis (Chair)**  
Salt Lake City, UT, USA

**Ofelia Noceti (Vice-Chair)**  
Montevideo, Uruguay

**Edgar Spencer**  
England, UK

**Denise McKeown**  
Glasgow, UK

**Franck Saint-Marcoux**  
Limoges, France

**Nicolas Picard**  
Limoges, France

**Maria Shipkova**  
Stuttgart, Germany

**Eberhard Weiland**  
Stuttgart, Germany

**Violette Gijzen**  
Rotterdam, The Netherlands

**Paula Schaiquevich**  
Buenos Aires, Argentina

**Olga Millan Lopez**  
Barcelona, Spain

**Alain Verstraete**  
Gent, Belgium

**Manuela Neuman**  
Toronto, Canada

**Ryuji Kato**  
Osaka, Japan

**Sarah Wille**  
Brussels, Belgium

**Jana Stojanova**  
Chile, South America

**Markus Meyer**  
Heidelberg, Germany

**Lewis Couchman**  
London, UK

# Thank you

Denise McKeown  
Glasgow, UK



Maria Shipkova  
Stuttgart, German



- Local Organizing Committee (Andrew McLachlan, Ross Norris, Lidia Dalton, Stephanie McMahon)
- IATDMCT Office (Amy Jiang, Pamela Lyons)
- Communication Committee members
- IATDMCT Council



#### Invitation to attend

The 18th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology (IATDMCT) 2018 will be held from Sunday 16th to Wednesday 19th September 2018 in Brisbane, Australia. IATDMCT 2018 will bring together leading international scientists and healthcare professionals, all actively working in the fields of Therapeutic Drug Monitoring and Clinical Toxicology. The theme of the congress is **Top Science Down Under**.

The congress will consist of world class keynote speakers, interactive symposia and practical workshops across all the major areas of therapeutics and training with a unique "Team and/or Future" theme. The congress will provide the opportunity for researchers and clinicians from around the world to come together and share their research and experiences in basic, clinical and translational pharmacology and clinical toxicology.

Brisbane has been voted cities' most innovative, internationally recognized hospitals and research institutes, as well as being an ideal venue with a comprehensive program and an ideal venue for enjoying some of the great attractions that Australia and New Zealand have to offer. It is just a short flight to the vibrant Sunshine Coast Great Escape. Meet & greet drinks in the Gold Coast beaches, or a short drive to Brisbane in national parks.

Plan your presentation and please join us to expand your knowledge and networks – and our knowledge and network – and make new friends.

See you in Brisbane in 2018!

A Prof Ross Norris and Professor Andrew McLachlan  
Co-Chairs, IATDMCT 2018 Local Organizing Committee

#### Who should attend?


The congress is open to professionals with an interest in either therapeutic drug monitoring and clinical toxicology and related disciplines, and is relevant for:

- Drug poison experts
- Clinical pharmacologists
- Clinical toxicologists
- Physicians
- Pharmacists
- Laboratory clinicians

#### Important dates

**Abstract submission opens** 1 September 2017  
**Registration opens** 1 September 2017  
**Registration closes** 16 October 2017  
**Temporary submission deadline** 28 February 2018  
**Abstract submission deadline** 28 February 2018  
**Abstract notification to authors** 28 April 2018  
**Early registration deadline** 20 June 2018  
**Accommodation booking deadline** 11 August 2018  
**Congress** 16-19 September 2018

[www.iatdmct2018.org](http://www.iatdmct2018.org)



# Compass Quarterly Newsletter

■ Compass team have done an outstanding job during 2018!



■ Associate Editor



Edgar Spencer  
England, UK



Editor-in-Chief



Paula Schaiquevich  
Buenos Aires, Argentina



Associate Editor



Franck Saint-Marcoux  
Limoges, France



# IATDMCT Social Media Team

---

- @IATDMCT on Twitter (>3000 tweets, 986 followers)

Purpose: real time information on the latest topics

Managers: Olga Millan, Jana Stojanova, Ryuji Kato, Nicolas Picard, Lewis Couchman

- IATDMCT Group on LinkedIn (780 members)

Purpose: interactive scientific discussion

Managers: Ofelia Noceti, Maria Shipkova, Ryuji Kato

- IATDMCT Blog (monthly posts)

Purpose: on-line space to communicate to members and non-members

Posts: interviews with IATDMCT members, news highlights


Author: Jana Stojanova, Editors: Denise McKeown & Maria Shipkova

- IATDMCT Facebook (145 likes, 154 friends)

Purpose: informal platform to communicate scientific news

Manager: Violette Gijsen, Kamisha Johnson-Davis


■ **Thank you team!**





# Blog 2018

MONTH	BLOG TOPIC	NUMBER OF HITS
JANUARY	TEUN VAN GELDER	746
FEBRUARY	JIANGTAO TANG	392
MARCH	KAMISHA JOHNSON-DAVIS	374
APRIL	MANUELA NEUMAN	330
MAY	Influence of Inflammation on Voriconazole metabolism	274
JUNE	2017 Charles Pippenger and Irvine Sunshine Award Winners	155
JULY	NICOLAS PICARD	110
AUGUST	JENNIFER MARTIN	92
SEPTEMBER	INDY SANDARADURA	
	ANDREW MCLACHLAN	
	SOPHIE STOCKER	



# IATDMCT Communication Activities

- IATDMCT E-News (monthly)
  - Purpose: Latest topics & news communicated via email to members
  - Topics: Office news, Congress updates, advertisements etc
  - New report of academic activities of members from the Scientific Committees
  - Co-Editors: Maria Shipkova and Manuela Neuman
  
- LWW TDM Journal Adverts (every issue)
  - Purpose: free advertising space to promote IATDMCT
  - Adverts: Congress 2018, social media, website resources, scientific committees
  - Managers: Denise A McKeown





# IATDMCT Congress 2018



@IATDMCT

- **Tweet @IATDMCT with your news & events**

- #IATDMCT
- #TDM
- #CT
- Congress Now Trending #IATDMCT2018

- **Tweet @IATDMCT with your Hot Topics!**

- The Science
- Office News
- Roundtables
- Workshops
- Sponsor News
- Social Events



Visit Us on  
FACEBOOK



Follow our  
BLOG




Join Us on  
LINKEDIN

[www.iatdmct.org](http://www.iatdmct.org)


[communications@iatdmct.org](mailto:communications@iatdmct.org)

<https://iatdmct2018.org/>



# IATDMCT Congress 2018

- Remember to download the Congress App for up to date information for the Congress
- 2<sup>nd</sup> Congress to provide Local Poster Printing Service





International Association of Therapeutic Drug Monitoring  
Annual General Meeting | Tuesday, September 18, 2018

## Education Director Report

**Erik van Maarseveen**

UMC Utrecht

**Katharina Rentsch**

University Hospital Basel


**Staffan Rosenborg**

Karolinska University Hospital

# •Activities of Directors of Education

---


- Posting of webcast presentation of previous meetings on Resources area
  - Including promotions in IATDMCT e-news updates
- Selection of talk taping for Brisbane congress
- First educational symposium at 2018 congress
  - Highlight!




# Future plans of Directors of Education

---


- Online posting congress materials asap after congress
  - For early access to IATDMCT members
- Discuss online Drug monographs in resources area
  - In close collaboration with IATDMCT SCs







# 2017 European Office Editorial Report



Prof. Dr. med Dr. h.c. Michael Oellerich  
FAACC, FAMM, FFPATH (RCPI), FRCPATH  
Editor-in-Chief

Prof. Philip N. Patsalos  
PhD, FRCPATH  
Associate Editor



Hannah Hempstead  
Managing Editor Europe



# Impact Factor 1996 – 2017

- 1996 – 1.829
- 1997 – 1.836
- 1998 – 1.543
- 1999 – 1.383
- 2000 – 1.732
- 2001 – 2.049
- 2002 – 2.140
- 2003 – 2.372
- 2004 – 2.798
- 2005 – 2.718
- 2006 – 3.032
- 2007 – 2.392
- 2008 – 2.410
- 2009 – 2.429
- 2010 – 3.127
- 2011 – 2.491
- 2012 – 2.234
- 2013 – 1.926
- 2014 – 2.376
- 2015 – 2.094
- 2016 – 2.178
- 2017 – 2.092

**5 Year Impact Factor: 2.1332**



# Impact Factor 1995 - 2017




Professor Michael Oellerich  
begins his tenure as Editor-in-  
Chief of Therapeutic Drug  
Monitoring.

# Manuscript Influx

Manuscripts received by the European Office:



- 2009: 132
- 2010: 125
- 2011: 123
- 2012: 170
- 2013: 140
- 2014: 151
- 2015: 126
- 2016 : 142
- 2017: 171



# Manuscripts received by the European Office

The number of submissions received in 2017 were :

- Original Articles : 134
- Short Communications : 26
- Letters to the Editor : 8
- Review Articles: 3



# Acceptance Rates

---

For manuscripts *received* in 2017:

44% accepted

45% rejected after peer review


10% rapidly rejected

1% pending

Submitted manuscripts to the European Office by  
*Country of Origin* in 2017


## Top 10

- |                         |                       |
|-------------------------|-----------------------|
| 1. China : 32           | 6. Spain : 10         |
| 2. Japan : 20           | 7. Norway : 8         |
| 3. The Netherlands : 18 | 8. Germany : 7        |
| 4. France: 10           | 9. United Kingdom : 6 |
| 5. Italy : 10           | 10. Australia: 5      |





# Status of submitted manuscripts to the European Office in 2017

	Accept	Reject	Pending	Rapid Reject	Withdrawn
Australia	3	2			
Austria					
Belgium	1	2			
China	6	26			
Croatia	1				
Czech Republic	1			1	
Estonia	1				
France	6	4			
Germany	3	3	1		
India		2			
Iran		2			1
Italy	5	4			1
Japan	11	9			
Lebanon		1			
Morocco		1			
Netherlands	13	5			
New Zealand					
Nigeria		2			
Norway	6	2			
Palestine		1			
Poland		5			
Portugal					
Saudi Arabia		1			
Serbia & Montenegro	1	1			
Singapore		2			
Slovenia		1			
South Korea	2				
Spain	5	5			
Sweden	2				
Switzerland	1	1			
Taiwan	1	1			
Thailand		1			
Tunisia		1			
Turkey		2			1
UK	4	2			
USA	2				



# All submitted manuscripts in 2017 by *Country of Origin*






# 2017 Turnaround Times

---

- The time from submission to published ahead of print: 21 weeks
  - The time from acceptance to published ahead of print: 5 weeks
  - The time from submission to print : 29 weeks (2016: 25 weeks)
  - The time from acceptance to print : 13 weeks (2016: 12 weeks)
- The page usage quota was 800 pages for 2017 (2016: 840). 686 pages in total were used against the budget, meaning we were under the budget by 154 pages.
- The current European backlog (after the August 2018 issue) includes 5 manuscripts.



# Manuscript Rating

In % of total accepted and rejected manuscripts

## 2017

Priority 1: 1%  
 Priority 2: 17%  
 Priority 3: 40%  
 Priority 4: 42%

## 2014:

Priority 1: 3%  
 Priority 2: 35%  
 Priority 3: 57%  
 Priority 4: 5%

## 2016:

Priority 1: 1%  
 Priority 2: 14%  
 Priority 3: 28%  
 Priority 4: 57%

## 2013:


Priority 1: 1%  
 Priority 2: 32%  
 Priority 3: 57%  
 Priority 4: 10%

## 2015:



Priority 1: 2 %  
 Priority 2: 18%  
 Priority 3: 50 %  
 Priority 4: 30%


## 2012:

Priority 1: 5%  
 Priority 2: 33%  
 Priority 3: 49%  
 Priority 4: 13%




# 2017 Manuscript Rating





# 2018 Interim European Office Editorial Report



Prof. Dr. med Dr. h.c. Michael Oellerich  
FAACC, FAMM, FFPATH (RCPI), FRCPath  
Editor-in-Chief

Prof. Philip N. Patsalos  
PhD, FRCPath  
Associate Editor



Hannah Hempstead  
Managing Editor Europe

International Association of Therapeutic Drug Monitoring & Clinical Toxicology | Annual General Meeting, September 18, 2018

# Acceptance Rates 2018\*

For manuscripts **received** in 2018:

26% accepted

26% rejected after peer review


9% rapidly rejected

39% pending

Submitted manuscripts to the European Office by  
***Country of Origin*** in 2018

## Top 10



- |                 |                         |
|-----------------|-------------------------|
| 1. China : 16** | 6. Norway : 3           |
| 2. Japan : 6    | 7. Australia: 2         |
| 3. France: 4    | 8. Iran: 2              |
| 4. Germany : 4  | 9. Croatia: 1           |
| 5. Italy : 3    | 10. The Netherlands : 1 |



# Manuscripts received by the European Office

The number of submissions received in 2018\* are:

- Original Articles : 49
- Short Communications : 3
- Letter to the Editor : 1




# 63 Turnaround Times


---

- The time from submission to published ahead of print: 14 weeks
  - The time from acceptance to published ahead of print: 1 week
  - The time from submission to print : 26 weeks (2017: 29 weeks)
  - The time from acceptance to print : 14 weeks (2017: 13 weeks)
- The page usage quota is 800 pages for 2018 (2017: 800). 396 pages in total have been used against the budget, meaning 444 pages are left.
- The current European backlog (after the August 2018 issue) includes 5 manuscripts.

## Manuscript Rating

Priority 1: 0%  
Priority 2: 15%  
Priority 3: 56%  
Priority 4: 29%





## 2018 Interim Denver Office Editorial Report\*

**Uwe Christians MD, PhD**  
**Editor-in-Chief**


**Philip Patsalos, PhD**  
**Associate Editor**

**Maria Shipkova, MD**  
**Reviews Editor**

**Wanzhu Zhao, MA**  
**Managing Editor**

\*01/01/2018-06/12/2018

Submission types processed at the Denver Office: North America and Chinese Original Articles, all Review Articles.






# Acceptance Rate

---


From 01/01/2018 to 06/13/2018

- Total manuscripts received: 67
- Accept: 40%
- Reject: 46%
- Pending: 13%



# Manuscripts Ratings (1-5)

Article Type	Clinical relevance	Scientific or clinical contribution	Presents new information	Priority
Original Manuscript	2.49	2.6	2.43	2.55
Review Article	2.46	2.75	2.92	2.58
Adjusted Averages	2.233	2.59	2.62	2.66



---


# Editorial Office Turnaround Time

	Average Number of Days
Submission to Editor Assignment	0.7 (2017: 1.9)
Submission to Reviewer Invitation	1.2 (2017: 3.6)
Submission to First Decision	29.8 (2017: 38.4)

# Production Turnaround Time

	Average Number of Weeks
Submission to In Production	11 weeks
Final Decision to In Production	3 weeks
Submission to Actual Print	26 weeks





## 2018 Editorial Report\*

**Uwe Christians MD, PhD**


**Editor-in-Chief**

**Philip Patsalos, PhD**  
**Associate Editor**

**Maria Shipkova, MD**  
**Reviews Editor**

**Wanzhu Zhao, MA**  
**Managing Editor**

\*After 06/13/2018




# Acceptance Rate

---


From 06/13/2018- now

Total manuscripts received: 49


- Accept: 4%
- Reject: 20%
- Pending: 76%





# Submission Types



Original Manuscript	32
Review Article	10
Letter to the Editor	3
Short Communication	3
Grand Round	1



# Manuscripts Received by Country of Origin



---

# Editorial Office Turnaround Time

	Average Number of Days
Submission to Editor Assignment	1.3 (2017: 1.9)
Submission to Reviewer Invitation	3.6 (2017: 3.6)
Submission to First Decision	20.3 (2017: 38.4)

# Production Turnaround Time

	Average Number of Weeks
Submission to In Production	4 Weeks
Submission to PAP	No sufficient Data
Submission to Print	No sufficient Data





# Issue Page Usage Report

---


The current European backlog (after the December 2018 issue) includes 6 manuscripts.

Issue Month	Total Pages counted against budget	# pages over (+)/under(-) allowance
Feb	163	22
Apr	131	-10
June	102	-38
Aug	137	-3
Oct	148	9
Dec		





# Manuscripts Ratings (1-5)

Article Type	Clinical relevance	Scientific or clinical contribution	Presents new information	Priority
Letter to the Editor	2.5	2.33	2.67	2.33
Original Manuscript	2.12	2.7	2.48	2.68
Review Article	2.5	2.75	2.75	2.75
Short Communication	3	3	2	3
Adjusted Averages	2.53	2.7	2.48	2.69




# Impact Factor 1996-2017

- 1996 – 1.829
- 1997 – 1.836
- 1998 – 1.543
- 1999 – 1.383
- 2000 – 1.732
- 2001 – 2.049
- 2002 – 2.140
- 2003 – 2.372
- 2004 – 2.798
- 2005 – 2.718
- 2006 – 3.032
- 2007 – 2.392
- 2008 – 2.410
- 2009 – 2.429
- 2010 – 3.127
- 2011 – 2.491
- 2012 – 2.234
- 2013 – 1.926
- 2014 – 2.376
- 2015 – 2.094
- 2016 – 2.178
- 2017 – 2.092



# Current Editorial Office Manuscript Status

	Accept	Revision	Pending
Belgium	1	1	
Brazil			3
China			9
Colombia			1
France	1		5
Germany	2	3	2
Iran		1	
Italy	1	1	
Japan			2
KOREA, REPUBLIC OF			3
Mexico			1
Netherlands		1	3
Norway		1	2
Poland		1	1
South Africa		1	
Spain			2
Sweden		1	
United Kingdom			3
United States	1	6	3



# Social Media Presence: Facebook



Page Views

94%



Page Previews

400%



Page Likes

200%



Reach

306%




Post Engagement

32%



Page Follower

200%




# Social Media Presence: LinkedIn

---

<b>Average audience reached</b>	<b>703</b>
Laboratory Scientist	56
Pharmacist	48
Research/Graduate Assistant	37
University Professor/Lecturer	36
Student/Intern	26
Salesperson	24
CEO/Executive Director	21
Medical Assistant/Technician	20
Clinical Research Specialist	16

Data analysis based on most recent LinkedIn post





International Association of Therapeutic Drug Monitoring  
Annual General Meeting | Tuesday, September 18, 2018

## **Alternative sampling strategies Committee**

**Jan-Willem Alffenaar, PhD, PharmD, Clinical Pharmacologist (Chair)**

University Medical Center Groningen

University of Groningen, Groningen, The Netherlands

**Christophe Stove, PhD (Vice-Chair)**

Laboratory of Toxicology, Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium

# Committee Membership

---

- **Current Members**


- Jan-Willem Alffenaar
- Christophe Stove
- Yngve Berqvist
- Michael Boettcher
- Begoña Delgado-Charro
- Pleasant Hooper
- Brian Keevil
- Rafael Linden
- Jan Gerard Maring
- Roland Meesters

- Leo Stolk

- Birgit Koch
- Constantinos Pistos
- Remco Koster

- **Past Members**

- Bert Ooms (retired)
- Otto Halmingh (stopped because of policy change of the Company)






# Activities

---

## ■ DBS Guideline


- This guideline defines key elements necessary for the validation of dried blood spot analysis.
- Guidance and criteria are given on the application of these validated methods in the routine analysis of
  - non-regulatory study samples from animal and human studies
  - samples from routine TDM.



# Activities

---

- Guideline development
  - Drafted outline of the guideline
  - Draft of different chapters followed by monthly Skype meeting
  - Circulation of drafted chapter within committee for critical review and feedback
  - Final draft circulated within committee
- Presentation at IATDMCT Congress in Kyoto Japan.
- **Artwork is being finalized (Sept 2018)**
- Submission to TDM journal for publication (Oct-Nov 2018)



# Activities

56<sup>TH</sup> ANNUAL MEETING OF THE INTERNATIONAL  
ASSOCIATION OF FORENSIC TOXICOLOGISTS (TIAFT) 2018

# TIAFT2018


26-30 / 08  
GHENT BELGIUM

PROGRAM &  
ABSTRACT BOOK

PROGRAM &  
ABSTRACT BOOK



IATDMCT & TIAFT Joint Young  
Scientist Symposium at  
TIAFT2018 (Ghent, Belgium)




# Publications

---

## ■ Compass

- March '18 edition: Oral fluid – a suitable specimen for compliance testing in psychopharmacotherapy and substitution therapy by M Böttcher and O Beck
- June '18 edition: Dried blood spot sampling in direct oral anticoagulants, what is the future? by C Pistos
- Sept '18 edition: Measurement of testosterone concentration in dried blood samples with haematocrit correction by D Marshall and BG Keevil



# Output


---

- Presentations

- n ~ 10

- Peer reviewed papers related to alternative sampling:

- n ~ 30



# Clinical Toxicology and Drugs of Abuse Committee

## Aims

- To provide evidence-based recommendations for CTDOA scientists, clinicians, laboratory and health care personal about of drugs of use and misuse
- To promote the knowledge and understanding of drug analysis, clinical toxicological normal and abnormal values and interpretation of results
- To enhance communication between scientists and physicians of all disciplines involved in CT of therapeutics and drugs of misuse
- To encourage the effective application of CT in all aspects of medicine, with the aim of optimizing clinical therapeutic use, avoid drug adverse reactions or interaction between drugs of use and misuse and maximizing the clinical and economic benefits



# Clinical Toxicology and Drugs of Abuse Committee

## Committee Achievements for 2018

- Organizing and participation in Symposia and workshops
  - IATDMCT Congress, Brisbane 2018. Organization and active participation in symposia and oral and poster presentations.
  - Organization : Alcohol and Drugs (Rehovot, Israel , July, 2017), Alcohol and Gut -Liver Axis, Satellite Symposium for Research Society on Alcoholism (San Diego, CA, June 2018)、 Canadian Society for Pharmacological Sciences, Toronto, ON, Canada, July 2018 ;
  - Speakers: The Ontario Society for Clinical Chemistry (Toronto, ON, Canada — November 2017), Canadian Society for Clinical Chemistry (Ottawa, ON, Canada, June 2018) , Symposium on *Risk factors for Alcoholic Liver Disease* in International Association for Biological Research on Alcoholism 2018 Congress, (Kyoto, Japan, September 2018)



# Clinical Toxicology and Drugs of Abuse Committee


---

- Participation in Symposiums and workshops
- IATDMCT
- Active participation in the Compass

Members of the Committee wrote articles for each issue publish at the Compass

New members of our Committee

Cristiana Stefan	Toronto	Canada
Minodora Dobreanu	Targu Mures	Romania
Daniel Kolnick	Haifa	Israel





# Clinical Toxicology and Drugs of Abuse Committee


## Committee Initiatives for 2019

### ■ Participation in Symposiums and workshops

- Proposals for Plenary Lectures, Symposiums, workshops , and contributed papers for The 17<sup>TH</sup> IATDMCT Congress Iguacu, Brazil, 22-25 September 2019.
- Symposium on *Personalized Medicine* Meeting. Jerusalem, Israel、 July 2019
- Symposium on Alcohol and Cancer, Road Island, USA, April 2019
- Symposium on Alcohol and Microbiota, RSA, Minneapolis, USA, 2019
- Symposium on Stellate cell and Liver Fibrosis, Toronto, Canada, 2019

### Active participation in the Compass

- We are going to participate with 6 reports during 2019.



# Clinical Toxicology and Drugs of Abuse Committee

---

- **Active participation in supplying materials for the e-news, website, including educational materials**


Kamisha Johnson Davis and Manuela Neuman will coordinate the contribution of the Communication Committee

Maria Shipkova (TDN Sc Committee) and Manuela Neuman will edit e-News for Communication Committee

- **Participation in a review manuscript on:** Biomarkers for Drug-induced Liver Injury to be published in TDM Journal in 2019. Editor: Maria Shipkova

- **Establishing Consortiums to facilitate:**

- Multi-centric research projects
- Inter-laboratory validation and quality control
- Consensus documents and guidelines
- Publications



# Clinical Toxicology and Drugs of Abuse Committee

## Committee Initiatives for 2019

### ■ Initiatives of the Working Groups

#### ○ The Biomarkers Working Group

- Innovative approach in personalized and precision medicine
- Pharmacokinetic
- Immuno-toxico-kinetics
- Drug Discovery
- Interaction between drugs of use and misuse
- Herbal-induced injury to different organs
- Infectious disease and therapeutic interactions
- Biomarkers in hypersensitivity Syndrome
- Pharmacogenetic and Justice
- Continue collaboration between the members of the committee
- Collaboration with several national and international scientific organization



# Immunosuppressive Drugs Scientific Committee

## Background & Purpose

- To provide evidence-based recommendations for TDM of immunosuppressive agents
- To promote the knowledge and understanding of immunosuppressive drug analysis and interpretation of results
- To enhance communication between scientists and physicians of all disciplines involved in TDM of immunosuppressive drugs
- To encourage the effective application of TDM in transplant medicine, with the aim of optimizing clinical drug use and maximizing the clinical and economic benefits



**Chair: Mercè Brunet**

**Vice-Chair: Stein Bergan**

# Immunosuppressive Drugs Scientific Committee


## Committee Achievements for 2018

### ■ Consensus Documents

- *Therapeutic Drug Monitoring of Tacrolimus-personalized Therapy: Second Consensus Report.* Status: editing the whole document to be published in TDM at the end of 2018. Participants: practically *all* members of the Immunosuppressive Drugs Scientific Committee (ISDs SC) and some members from the SC of PG. Coordinators: Mercè Brunet and Stein Bergan.

### ■ Participation in Symposia and workshops (I)

- IATDMCT Congress, Brisbane 2018. Active participation in symposia (1, 2, 5, 14, 16) and contributed papers.
- Participation in The 13th Congress of the Polish Transplantation Society, Session: Biomarkers combined with TDM of Immunosuppressive Drugs. Warsaw, October 2017. Participants: M. Brunet, D. Hesselink. Chairs: T. Pawinski, P. Kunicki.
- Symposium on *Personalized Immunosuppression to improve clinical outcomes* in EUROMEDLAB 2019 Congress, SECO Joint Scientific Meeting in Barcelona, May 2019. *23<sup>rd</sup> European Congress of Clinical Chemistry and Laboratory Medicine.* Proposal approved by the scientific committees, May 2018. Participants: F. Lemaitre, M. Brunet, T. van Gelder.



# Immunosuppressive Drugs Scientific Committee


## Committee Achievements for 2018

### ■ Participation in Symposia and workshops (II)

- IATDMCT Symposium at the 15th Annual Congress of the DGKL "Laboratory medicine – the foundation for diagnosis and treatment", 26-29 September 2018, Mannheim, Germany. Lecture: *TDM of tacrolimus updated: introducing a new IATDMCT consensus document (Analytical Section)*, M. Shipkova. Chairs: C. Seger and M. Shipkova.
- IATDMCT Symposium at the 5th EFLM-UEMS European joint Congress "Laboratory Medicine at the clinical Interface". Lecture: *Therapeutic drug monitoring in transplant patients*, E Wieland. October 2018.

### ■ Active participation in the Compass

- First report, *Insight miRNAs as Biomarkers in Clinical Transplantation* by O. Millán & M. Brunet, was published in COMPASS Vol17 issue 2, June 2018.
- Second report, *Therapeutic drug monitoring of Mycophenolic acid products: Evidence and Knowledge gaps, laboratory and clinical experience* by T. van Gelder, will be published in COMPASS Issue 4, November 2018.



# Immunosuppressive Drugs Scientific Committee

## Committee Achievements for 2018

### ■ Achievements of the Working Groups of the Immunosuppressive Drugs Committee

#### ○ The Biomarkers Working Group\*

Contribution of Section "Pharmacodynamic Biomarkers for TAC Monitoring" to *Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Report*. Participants: O. Millán, C. Sommerer, O. Noceti. Lead: E. Wieland, K. Budde.

Contribution of manuscript "Pharmacodynamic Monitoring of mTOR inhibitors" to *Therapeutic Drug Monitoring Focus Issue*. Participants: O. Millán, P. Marquet, E. Wieland, M. Brunet. Lead: M. Shipkova.


\*Leader: Uwe Christians

#### ○ The Intracellular tacrolimus measurement Working Group\*

*Measuring intracellular concentrations of immunosuppressive drugs: recommendations from the International Association for Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) expert panel for calcineurin inhibitors*. Manuscript to be published in TDM Journal 2018/2019. Participants: N.T. Vethe, A.

D'Avolio, C. Tron, I. Robertsen, B. De Winter, A. Denicolo, Birgit Koch, T. Van Gelder, M. Brunet, S. Bergan, D. Hesselink, and P. Wallemacq. Lead: F. Lemaitre.

\* Leader: Florian Lemaitre




# Immunosuppressive Drugs Scientific Committee

## Committee Achievements for 2018

- **Achievements of the Working Groups of the Immunosuppressive Drugs Committee (II)**
- **Standardization of ISDs TDM Working Group\***
- Immunosuppressive Drugs WG-ID was established by the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC).
  - Terms of Reference: The WG is devoted to the establishment of candidate reference procedures and reference materials for immunosuppressive drugs (ISDs) as cyclosporine, sirolimus, tacrolimus, everolimus, and mycophenolic acid (MPA). Demonstration of the current state of the art in ISDs-TDM by measurement comparison will define the need for harmonization or-if feasible standardization of measurement services.
  - Current projects:
    - Regulatory frame work: Submit to the JCTLM reference materials, measurement methods and measurement services established within the WG-ID.
    - Other projects, initiatives for 2019

\*Leaders: Christoph Seger, Loralie Langman





# Immunosuppressive Drugs Scientific Committee

## Committee Initiatives for 2019

### ■ Participation in Symposiums and workshops

- Proposals for Plenary Lectures, Symposiums, workshops , and contributed papers for The 17<sup>TH</sup> IATDMCT Congress Iguacu, Brazil, 22-25 September 2019.
- Symposium on *Personalized Immunosuppression to improve clinical outcomes* in EUROMEDLAB 2019 Congress & SECQ Joint Scientific Meeting. Barcelona, May 2019. F. Lemaitre, M. Brunet, T. van Gelder.

### ■ Active participation in the Compass

- We are going to participate with 2 reports during 2019.

### ■ Active participation in supplying materials for the website, including educational materials

Mercè Brunet and Stein Bergan will coordinate the contribution of the Committee.

- **Participation in a review manuscript on:** TDM and immunosuppressive drugs: originals and generics. With the participation of members of the ISDs Committee. To be published in TDM Journal in 2019. Leaders: T. Pawinski & P.




# Immunosuppressive Drugs Scientific Committee

---

## Committee Initiatives for 2019

- Consider Establishing Consortia to facilitate:
  - Multicentric research projects
  - Inter-laboratory validation methodologies
  - Consensus documents and guidelines



# Immunosuppressive Drugs Scientific Committee

## Committee Initiatives for 2019

### ■ Initiatives of the Working Groups (I)

#### ○ The Biomarkers Working Group

Second Consensus Document on Biomarkers of ISDs in Transplantation. Participants: all members of the BWG.

Leader: Uwe Christians

#### ○ The Intracellular tacrolimus measurement Working Group

Consider an external quality control program

Proposal: Coordinate a clinical trial to determine the therapeutic range for intracellular IS drugs concentrations. Participants: all members of the WG.

Leader: Florian Lemaitre

#### ○ Standardization of ISD TDM Working Group (WG-ID)

The analytical standardisation driven by the IFCC and a committee co-chaired by L. Langman and C. Seger, and the implementation of the standardisation leading to all laboratories providing “identical” results, which will be driven by the ISDs Committee. Participants: M.J. Barten, S. Bergan, M. Brunet, U. Christians, B. De Winter, L. Elens, D.W. Holt, P.K: Kunicki, S. Masuda, D. Moes, T. Pawinski, L.M. Shaw, M. Shipkova, N. Tore Vethe, T. Van Gelder, P. Wallemacq, E. Wieland.

Leaders: Christoph Seger, Loralie Langman



# Immunosuppressive Drugs Scientific Committee

## Committee Initiatives for 2019

### ■ Initiatives of the Working Groups (II)

#### ○ Standardization of ISDs TDM Working Group (Cont.)

WG-ID Projects:

- Measurement comparison initiative aimed to assess the state of the art in ISD TDM
- Production of reference materials on method comparability.
- Establishment of reference methods to be listed in the JCTLM database
- Establishing reference procedures: Establishment of a reference laboratory network and a - reference measurement service network

Leaders: Christoph Seger, Loralie Langman






# IATDMCT Immunosuppressive Drugs Committee Members II

## Members

Surname	Forename	Location
Lemaitre	Florian	Rennes, France
MacPhee	Iain	London, UK
Marquet	Pierre	Limoges, France
Mason	Donald	Milford, MA, USA
Masuda	Satohiro	Fukuoka, Japan
Mathew	Binu	Vellore, India
Millán	Olga	Barcelona, Spain
Milone	Michael	Philadelphia, PA, USA
Moes	Dirk-Jan	Leiden, Netherlands
Morris	Ray	Adelaide, SA, Australia
Noceti	Ofelia	Montevideo, Uruguay
Oellerich	Michael	Göttingen, Germany
Pawinski	Tomasz	Warsaw, Poland
Seger	Christoph	Innsbruck, Austria
Shaw	Les	Philadelphia, PA, USA
Shipkova	Maria	Stuttgart, Germany
Taylor	Paul	Brisbane, QLD, Australia



# IATDMCT Immunosuppressive Drugs Committee Members III

---

## Members

Surname	Forename	Location
van Gelder	Teun	Rotterdam, Netherlands
van Schaik	Ron	Rotterdam, Netherlands
Vethe	Nils Tore	Oslo, Norway
Vinks	Sander	Cincinnati, OH, USA
Wallemacq	Pierre	Brussels, Belgium
Wang	Ping	Houston, TX, USA
Wieland	Eberhard	Stuttgart, Germany



# Members of the PGx Committee

---

**Vincent Haufroid (chair)**

University of Louvain, Brussels, BE

**Iain McPhee**

St George's University London, UK

**Tsuyoshi Fukuda**

Cincinnati children's Hospital, USA

**Nicolas Picard (vice chair)**

Limoges University Hospital, FR

**Ron van Schaik**

Erasmus MC Rotterdam, NL

**Steven Wong**

Wake Forest School of Med., USA

**Teun van Gelder**

Erasmus MC Rotterdam, NL

**Laure Elens**

University of Louvain, Brussels, BE

**Jana Stojanova**

University of Valparaiso, Chile

**Mark Linder**

University of Louisville, USA

**Stein Bergan**

Oslo University Hospital, NO

**Andrew Somogyi**


University of Adelaide, Australia

**Werner Steimer**

Technische Universität München, GER

**Jesse Swen**

Leiden University MC, NL





# Recent activities

---

- Publications in TDM journal


**Haufroid V** and **Picard N** (2018) Pharmacogenetic biomarkers predictive of drug pharmacodynamics as an additional tool to therapeutic drug monitoring (invited editor: Shipkova M). *Ther Drug Monit, submitted on July 31th*

**Haufroid V**, **Picard N**, Hesselink D, **Elens L**, Masuda S, **Van Schaik R** (2018) Contribution to the pharmacogenetic chapter for the second consensus report on Tacrolimus TDM (invited editors: Brunet M and Bergan S). *Ther Drug Monit, in submission*

- Contribution in IATDMCT compass

**Picard N** and **Haufroid V** on behalf of the Pharmacogenetics Committee. Pharmacogenetic-based personalized therapy: The French national network of pharmacogenetics (RNPGX) proposed levels of evidence and recommendations. *IATDMCT Compass March 2017: 4-5*

Next contribution to the IATDMCT compass; *November 2018*



# Recent activities

---


- Organization of the PGx session for Brisbane 2018

**Linder M** and **Somogyi A** (chairs of the PGx session) **Pre-emptive pharmacogenetics testing: is this the right approach?**

1. Linder M, USA
2. Guchelaar H.J., The Netherlands
3. Dunnenberger M, USA
4. Wang Y.T., China

- Validation of minimal NGS panel for PGx applications

**Picard N** and **Haufroid V**, on behalf of the Pharmacogenetics Committee, in the French national network of pharmacogenetics (RNPGX). **Panel in validation**



# Connections

---


- AACC Personalized Medicine Division (RvS)
- IFCC Pharmacogenetic Task Force (RvS)
- ESPT (European Soc Pharmacogenetics) (RvS)
- EMA Pharmacogenetics Working Group (RvS)
- Dutch Pharmacy Group Pharmacogenetics (RvS, JS)
- Dutch Clinical Chem Pharmacogenetics Network (RvS, JS)
- French National Network of Pharmacogenetics, RNPGx (NP, VH)
- European Pharmacogenetics Research Network - EuPIC (RvS, VH, NP, LE, JS)
- H2020 European Project (UPGX) (JS, RvS)
- CPIC (RvS, VH, ML, JSv, JSt)




# Future activities

---

- Make proposal for IATDMCT PGx session in Foz Do Iguassu, Brazil, 2019
- Propose/validate a (minimal) NGS panel to be used for pharmacogenetic applications in the field of TDM and CT (to be published in IATDMCT Compass)
- Explore the need for updated PGx guidelines in immunosuppressive therapy





International Association of Therapeutic Drug Monitoring  
Annual General Meeting | Tuesday, September 18, 2018

## TDM in Oncology

**William Clarke, Chair**

Johns Hopkins Hospital, USA

**Jennifer Martin, Vice-Chair**

University of Newcastle, NSW Australia

**Yusuke Tanigawara**

Keio University SOM, Japan

**Jan Beumer**

University of Pittsburgh, USA

**Erik van Maarseveen**

UMC Utrecht, Netherlands

**Etienne Chatelut**

IUCT-Oncopole, France

**Edward Chu**

University of Pittsburgh Cancer Center, USA

**Alan Footohi**

Karolinska Institute, Sweden

**Paula Schaiquevich**

Unidad de Farmacocinetica Clinica, Argentina

**Sal Salamone**

Saladax Biomedical, USA

**Yuichi Ando**

Nagoya University Hospital, Japan


**Markus Joerger**


Cantonal Hospital, Switzerland

# Title of slide

---

- TDM in Oncology Guidelines
  - 5-Fluorouracil (completed)
  - Imatinib (draft in progress)
  - Paclitaxel (just starting)
- Publications
  - Review article to TDM journal (in revision)
  - Articles in Compass
  - 5-FU Guideline
- Other activities
  - Development of SOP for guideline review and publication
  - Transition of committee leadership





International Association of Therapeutic Drug Monitoring  
Annual General Meeting | Tuesday, September 18, 2018

## Toxicology and Environmental Health Scientific Committee

**Nicolas Venisse**

Toxicologie et Pharmacocinétique


**David Kinniburgh**

Alberta Centre for Toxicology

# Symposium at IATDMCT conferences

---

- Kyoto conference: A new Scientific Committee on Toxicology and Environmental Health at IATDMCT.
- Brisbane conference: Alternative matrix for the determination of human exposure to environmental pollutants






# Articles for Compass


---

- Presentation of the new SC committee (N Venisse, 2017 issue)
- Report from the Society of Toxicology (SOT) conference in San Antonio (S Haddad, june 2018 issue)
- General paper on Bioanalytical validation in Environmental Health Toxicology (Antoine Dupuis, sept 2018)
- Report on Biomonitoring program in Alberta, Canada (D Kinniburgh, 2018)



# Future contributions

- Development of a Bioanalytical validation guideline in environmental health toxicology. The objective is to develop an innovative tool allowing standardization and avoiding poor quality bioanalytical results. A questionnaire will be send to members of the scientific committee in order to develop this guideline. The consensus document could be presented at the 2019 conference as a post-congress workshop and published in a peer-reviewed journal.
- Symposium for 2019 conference
- Articles submission for Compass
- Proposal for a joint symposium at Society of Toxicology conference: Sami Haddad is an active member of both societies.





# International Association of Therapeutic Drug Monitoring Annual General Meeting | Tuesday, September 18, 2018

## Young Scientists Committee (YSC)

**Indy Sandaradura**  
Australia

**Markus R. Meyer (Chair)**  
Germany

**Sarah Wille**  
Belgium

**Takehito Yamamoto**  
Japan

**Brenda de Winter (Vice-Chair)**  
The Netherlands

**Nicolas Picard**  
France

**Laure Elens**  
Belgium



**Sumith K Mathew**  
India


**Kamisha Johnson-Davies**  
USA

**Tomoyuki Mizuno**  
USA

## Joint Symposium with TIAFT

- YSC of IATDMCT and YSC of TIAFT organized a successful joint symposium at the TIAFT conference in Ghent 2018
- Sunday 26<sup>th</sup> of August 09:00 – 12:30 h
- Brenda de Winter gave a talk about CT


→ over 150 YS attended



## Activities in Brisbane

---


- Wednesday 19 September 2018 - IATDMCT Young Scientist Symposium at 10:30-12:30 h
- Monday 17 September 2018 - YS Night Out “Young Scientists Dinner“ at 19:00 h
- YS get together right before the opening ceremony
- Young Scientist Awards (oral/poster)
- 23 entries (oral), 39 entries (poster)



## Frequent Compass Contributions (YS Corner)

---

- March 2018: Introducing new members of the YSC
- June 2018: Report about Analytica Conference 2018 - Joint Symposium with GTFCH and GDCH on "Trends in analytical toxicology - new matrices, new methods, new analytes"
- September: Brisbane congress activities



## Upcoming topics

---

- Succession ?
  - Markus will step down as chair in 2019
  - Takehito will step down in 2018 (Yusuke)
- Joint symposia with related YSC (TIAFT?)
- Increase YS activities at annual congresses
  - Expert speed dating

